MNPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Monopar Therapeutics Inc (MNPR) is not a strong buy at this time for a beginner, long-term investor with $50,000-$100,000 available. The stock lacks clear positive momentum, technical indicators are neutral, and there are no strong catalysts or trading signals to support immediate action. Holding or monitoring the stock for future developments is recommended.
The MACD is negative and contracting (-0.597), RSI is neutral at 41.426, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 60.77, with support at 56.017 and resistance at 65.523.
Morgan Stanley initiated coverage with an Overweight rating and a $115 price target, citing the potential of ALXN1840 as a differentiated therapy for Wilson's disease. Net income improved significantly YoY in Q3 2025, up 163.56%.
Technical indicators do not show a strong upward trend. No recent news or congress trading data to indicate heightened interest or momentum.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved to -$3,437,601 (up 163.56% YoY), and EPS increased to -0.48 (up 29.73% YoY). Gross margin remains at 0%.
Morgan Stanley initiated coverage with an Overweight rating and a $115 price target, citing encouraging prospects for ALXN1840 in treating Wilson's disease.
